Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Share-based Compensation: 2013-2017

Historic Share-based Compensation for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2017 value amounting to $1.8 million.

  • Tvardi Therapeutics' Share-based Compensation rose 118.34% to $1.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was $6.3 million, marking a year-over-year increase of 126.07%. This contributed to the annual value of $8.9 million for FY2024, which is 34.97% down from last year.
  • According to the latest figures from Q4 2017, Tvardi Therapeutics' Share-based Compensation is $1.8 million, which was down 13.56% from $2.1 million recorded in Q3 2017.
  • Tvardi Therapeutics' 5-year Share-based Compensation high stood at $2.1 million for Q3 2017, and its period low was $11,000 during Q2 2013.
  • In the last 3 years, Tvardi Therapeutics' Share-based Compensation had a median value of $742,000 in 2015 and averaged $970,333.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 4,045.45% in 2014, then dropped by 0.43% in 2016.
  • Quarterly analysis of 5 years shows Tvardi Therapeutics' Share-based Compensation stood at $13,000 in 2013, then spiked by 2,515.38% to $340,000 in 2014, then soared by 107.94% to $707,000 in 2015, then increased by 17.26% to $829,000 in 2016, then surged by 118.34% to $1.8 million in 2017.
  • Its Share-based Compensation was $1.8 million in Q4 2017, compared to $2.1 million in Q3 2017 and $1.3 million in Q2 2017.